Sign in

    ChukaWolf Research

    Chuka Ndulue is a Managing Director and Senior Equity Analyst at Wolf Research, focusing on U.S. and Latin American banks with coverage of prominent institutions such as JPMorgan Chase, Bank of America, Citigroup, Goldman Sachs, Banco Bradesco, and Itau Unibanco. Widely recognized for his expertise, Chuka has consistently ranked among the top bank analysts on platforms like TipRanks, boasting a success rate near 70% and generating above-market returns on his recommendations. He began his career at Goldman Sachs as a Research Analyst, later holding research positions at Barclays before joining Wolf Research in 2019. Chuka holds FINRA Series 7, 63, 86, and 87 licenses and has been featured in industry rankings for his in-depth analysis and high-performing investment calls.

    Chuka's questions to Kyverna Therapeutics Inc (KYTX) leadership

    Chuka's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024

    Question

    Speaking for Andy Chen, Chuka asked for clarification on the IRAK4 trial changes, questioning if Sanofi's addition of a dose was related to any safety or efficacy signals from previous doses.

    Answer

    Founder, President, and CEO Nellie Monofi clarified that the addition of a dose group is not due to any concerns about safety or efficacy. Instead, it is a strategic move to fulfill regulatory dose-ranging requirements, which will accelerate the program's path to Phase 3 registration studies upon completion of the current trials.

    Ask Fintool Equity Research AI